Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12629160 | 0.83 | FAAH (0.37) | CTSLCTSBCTSSCTSKMEN1 | |
| SCHEMBL10980085 | 0.83 | FAAH (0.37) | CTSLCTSBCTSSCTSKMEN1 | |
| SCHEMBL768534 | 0.79 | CA1 (0.47) | CTSLCTSBCTSSCTSKKMT2A | |
| SCHEMBL10985225 | 0.79 | CTSL (0.40) | CTSLCTSBCTSSCTSKMEN1 | |
| SCHEMBL2386106 | 0.79 | CA1 (0.47) | CTSLCTSBCTSSCTSKKMT2A | |
| SCHEMBL6632972 | 0.79 | CA1 (0.47) | CTSLCTSBCTSSCTSKKMT2A | |
| SCHEMBL17739742 | 0.78 | CTSS (0.37) | CTSLCTSBCTSSCTSKMEN1 | |
| SCHEMBL14779910 | 0.76 | ALDH1A1 (0.32) | JAK2JAK1JAK3ALDH1A1 | |
| SCHEMBL16761492 | 0.76 | ALDH1A1 (0.32) | JAK2JAK1JAK3ALDH1A1 | |
| SCHEMBL22736205 | 0.76 | ALDH1A1 (0.36) | MEN1KMT2AJAK2JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8491931-B2 | Treatment of faecal incontinence and other conditions with 1R, 2S-methoxamine | NORGINE BV (NL) | 2013-07-23 | — | — | US | disclosed |
| US-8491931-B2 | Treatment of faecal incontinence and other conditions with 1R, 2S-methoxamine | NORGINE BV (NL) | 2013-07-23 | — | — | US | disclosed |
| US-20130072567-A1 | TREATMENT OF FAECAL INCONTINENCE AND OTHER CONDITIONS WITH 1R, 2S-METHOXAMINE | NORGINE BV (NL) | 2013-03-21 | — | — | US | disclosed |
| US-20130072567-A1 | TREATMENT OF FAECAL INCONTINENCE AND OTHER CONDITIONS WITH 1R, 2S-METHOXAMINE | NORGINE BV (NL) | 2013-03-21 | — | — | US | disclosed |
| EP-2275099-A1 | Treatment of faecal incontinence with 1r,2s-methoxamine | Norgine Europe BV (NL) | 2011-01-19 | — | — | EP | disclosed |
| US-20100022657-A1 | Treatment of faecal incontinence and other conditions with 1R, 2S-methoxamine | NORGINE EUROPE BV | 2010-01-28 | — | — | US | disclosed |
| US-20100022657-A1 | Treatment of faecal incontinence and other conditions with 1R, 2S-methoxamine | NORGINE EUROPE BV | 2010-01-28 | — | — | US | disclosed |
| US-20050096397-A1 | Treatment of faecal incontinence and other conditions with 1r,2s-methoxamine | NORGINE EUROPE BV (NL) | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096397-A1 | Treatment of faecal incontinence and other conditions with 1r,2s-methoxamine | HTR1D, MTNR1A, ADRA1D | CTSL 4610/4885CTSB 4507/4885CTSS 3600/4885 |
| US-20100022657-A1 | Treatment of faecal incontinence and other conditions with 1R, 2S-methoxamine | HTR1D, ADRA1D, HTR1A | CTSL 4649/4885CTSB 4569/4885CTSS 3721/4885 |
| US-20130072567-A1 | TREATMENT OF FAECAL INCONTINENCE AND OTHER CONDITIONS WITH 1R, 2S-METHOXAMINE | HTR1D, ADRA1D, HTR1A | CTSL 4712/4885CTSB 4636/4885CTSS 3795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.